Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance

Obstetrics and Gynecology

Volumn 125, Issue 2, 2015, Pages 330-337

  Huh, Warner K ^a   Ault, Kevin A ^a   Chelmow, David ^a   Davey, Diane D ^a   Goulart, Robert A ^a   Garcia, Francisco A R ^a   Kinney, Walter K ^a   Massad, L Stewart ^a   Mayeaux, Edward J ^a   Saslow, Debbie ^a   Schiffman, Mark ^a   Wentzensen, Nicolas ^a   Lawson, Herschel W ^a   Einstein, Mark H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL EFFECTIVENESS; DIAGNOSTIC TEST; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; FALSE NEGATIVE RESULT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEALTH CARE PERSONNEL; HIGH RISK HUMAN PAPILLOMAVIRUS TESTING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MEDICAL SOCIETY; PATIENT CARE; PATIENT SAFETY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; STANDARDS; UTERINE CERVICAL NEOPLASMS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84922419672     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000669     Document Type: Review

References (24)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch F, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 2-9
2. Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: US preventive services task force recommendation statement. Ann Intern Med 2012; 156: 880-91
3. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11: 201-22
4. Saslow D, Solomon D, Lawson HW, KillackeyM, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 62: 147-72
5. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32
6. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012; 106: 975-81
7. Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012; 345: e7789
8. Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M. The HPV test has similar sensitivity but more overdiagnosis than the Pap test-A randomised health services study on cervical cancer screening in Finland. Int J Cancer 2013; 132: 2141-7
9. Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol 2012; 125: 343-5
10. Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-The HPV FOCAL Study. Br J Cancer 2012; 107: 1917-24
11. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol In press
12. US Food and Drug Administration. 2014 meeting materials of the microbiology devices panel. Available at: http://www. fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/Microbiology DevicesPanel/ucm388531.htm. Retrieved July 21, 2014
13. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57
14. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010; 340: c1804
15. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010; 11: 1160-71
16. Petry KU, Luyten A, Scherbring S. Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol 2013; 128: 282-7
17. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10
18. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754
19. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011; 47: 864-71
20. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12: 663-72
21. Gage J, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014; 106: 1-4
22. Liebrich C, Brummer O, Von Wasielewski R, Wegener G, Meijer C, Iftner T, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol 2009; 30: 45-8
23. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35
24. Hopenhayn C, Christian A, Christian WJ, Watson M, Unger ER, Lynch CF, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis 2014; 18: 182-9